CD274 and cancer: Since PD-L1 and immunocompetent cells in the TME have been suggested as potential predictors for patient outcomes on both tyrosine kinase inhibition (TKI) treatment and immunotherapy in various cancers [9,12,16,17,18], it was intriguing to see whether such TME signatures could have an impact on the natural course and crizotinib treatment of ASPS.